Cell cycle-related differences in susceptibility of NIH/3T3 cells to ribonucleases

Experimental Cell Research

Volumn 247, Issue 1, 1999, Pages 220-232

  Smith, Mark R ^a   Newton, Dianne L ^a   Mikulski, Stanley M ^b   Rybak, Susanna M ^c  

^a SAIC FREDERICK INC   (United States)

^b Alfacell Corporation   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cell; Cycle; NIH 3T3; Ribonuclease

Indexed keywords

BUCLADESINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; RAS PROTEIN; RIBONUCLEASE A;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL DEATH; CELL KILLING; CELL PROLIFERATION; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; MICROINJECTION; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0033602045     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1998.4317     Document Type: Article

References (43)

1. Youle R. J., Newton D. L., Wu Y. N., Gadina M., Rybak S. M. Cytotoxic ribonucleases and chimeras in cancer therapy. Crit. Rev. Ther. Drug Carrier Systems. 10:1993;1-28.
2. Ardelt W., Mikulski S. M., Shogen K. Amino acid sequence of an anti-tumor protein fromRana pipiens. J. Biol. Chem. 266:1991;245-251.
3. Mikulski S. M., Grossman A. M., Carter P. W., Shogen K., Costanzi J. J. Phase 1 human clinical trial of ONCONASE (P-30 protein) administered intravenously on a weekly schedule in cancer patients with solid tumors. Int. J. Oncol. 3:1993;57-64.
4. Rybak S. M., Saxena S. K., Ackerman E. J., Youle R. J. Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins. J. Biol. Chem. 266:1991;21202-21207.
5. Rybak S. M., Hoogenboom H. R., Meade H. M., Raus J. C., Schwartz D., Youle R. J. Humanization of immunotoxins. Proc. Natl. Acad. Sci. USA. 89:1992;3165-3169.
6. Newton D. L., Xue Y., Olsen K. A., Fett J. W., Rybak S. M. Angiogenin single-chain immunofusions: Influence of peptide linkers and spacers between fusion protein domains. Biochemistry. 35:1996;545-553.
7. Newton D. L., Nicholls P. J., Rybak S. M., Youle R. J. Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv. J. Biol. Chem. 269:1994;26739-26745.
8. Wu Y. N., Mikulski S. M., Ardelt W., Rybak S. M., Youle R. J. Cytotoxic ribonuclease: A study of the mechanism of Onconase cytotoxicity. J. Biol. Chem. 268:1993;10686-10693.
9. Lin J. J., Newton D. L., Mikulski S. M., Kung H. F., Youle R. J., Rybak S. M. Characterization of the mechanism of cellular and cell free protein synthesis inhibition by an anti-tumor ribonuclease. Biochem. Biophys. Res. Commun. 204:1994;156-162.
10. Saxena S. K., Rybak S. M., Winkler G., Meade H. M., McGray P., Youle R. J., Ackerman E. J. Comparison of RNases and toxins upon injection intoXenopus. J. Biol. Chem. 266:1991;21208-21214.
11. Thrush G. R., Lark L. R., Clinchy B. C., Vitetta E. S. Immunotoxins: An update. Annu. Rev. Immunol. 14:1996;49-71.
12. Rybak S. M., Newton D. L., Xue Y. RNase and RNase immunofusions for cancer therapy. Tumor Targeting. 1:1995;141-147.
13. Pastan I. H., Pai L. H., Brinkmann U., FitzGerald D. J. Recombinant toxins: New therapeutic agents for cancer. Ann. N.Y. Acad. Sci. 758:1995;345-354.
14. Schein C. H. From housekeeper to microsurgeon: The diagnostic and therapeutic potential of ribonucleases. Nature Biotechnol. 15:1997;529-535.
15. Wu Y. N., Saxena S. K., Ardelt W., Gadina M., Mikulski S. M., DeLorenzo C., D'Alessio G., Youle R. J. A study of the intracellular routing of cytotoxic ribonucleases. J. Biol. Chem. 270:1995;17476-17481.
16. Crestfield A. M., Stein W. H., Moore S. Properties and conformation of the histidine residues at the active site of ribonuclease. J. Biol. Chem. 238:1963;2420-2431.
17. Darzynkiewicz Z., Carter S. P., Mikulski S. M., Ardelt W. J., Shogen K. Cytostatic and cytotoxic effects of Pannon (P-30 protein), a novel anti-cancer agent. Cell Tissue Kinet. 21:1988;169-182.
18. Ma J. K. C., Hein M. B. Immunotherapeutic potential of antibodies produced in plants. TIBTECH. 13:1995;522-527.
19. Mikulski S. M., Viera A., Ardelt W., Menduke H., Shogen K. Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumor activity. Cell Tissue Kinet. 23:1990;237-246.
20. Mikulski S. M., Viera A., Darzynkiewicz A., Shogen K. Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. Br. J. Cancer. 66:1992;304-310.
21. Mikulski S. M., Viera A., Shogen K. In vitro. Int. J. Oncol. 1:1992;779-785.
22. Rybak S. M., Pearson J. W., Fogler W. F., Volker K., Spence S. E., Newton D. L., Mikulski S. M., Ardelt W., Riggs C. W., Kung H. F., Longo D. L. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with Onconase, an antitumor ribonuclease. J. Natl. Cancer Inst. 88:1996;747-753.
23. Smith M. R., Matthews N. T., Jones K. A., Kung H. F. Biological actions of oncogenes. Pharmacol. Ther. 58:1993;211-236.
24. Stacey D. W., Kung H. F. Transformation of NIH-3T3 cells by microinjection of Ha-ras p21 protein. Nature. 310:1984;508-511.
25. Feramisco J. R., Gross M., Kamata T., Rosenberg M., Sweet R. W. Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells. Cell. 1984;109-117.
26. Mulcahy L. S., Smith M. R., Stacey D. W. Requirements for ras proto-oncogene function during serum-stimulated growth of NIH/3T3 cells. Nature. 313:1985;241-243.
27. Smith M. R., DeGudicibus S. J., Stacey D. W. Requirement for c-ras proteins during viral oncogene transformation. Nature. 320:1986;540-543.
28. Koide H., Satoh T., Nakafuku M., Kaziro Y. GTP-dependent association of Raf-1 with Ha-Ras: Identification of Raf as a target downstream of Ras in mammalian cells. Proc. Natl. Acad. Sci. USA. 90:1993;8683-8686.
29. Warne P. H., Viciana P. R., Downward J. Direct interaction of Ras and the amino-terminal region of Raf-1 and mitogen activated protein kinase. Nature. 364:1993;352-355.
30. Moodie S. A., Willumsen B. M., Weber M. J., Wolfman A. Complexes of ras-GTP with Raf-1 and mitogen activated protein kinase kinase. Science. 260:1993;1658-1661.
31. Fadok V. A., Voelker D. R., Campbell P. A., Cohen J. J., Bratton D. L., Henson P. M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148:1992;2207-2216.
32. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled annexin V. J. Immunol. Methods. 134:1995;39-51.
33. Koopman G., Reutelingsperger C. P., Kuijten G. A., Keehnen R. M., Pals S. T., vanOers M. H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 84:1994;1415-1420.
34. Homburg C. H. E., deHass M., vondemBorne A. E., Verhoeven A. J., Reutelingsperger C., Roos D. Human neutrophils lose their surface Fc gamma RIII and acquire annexin V binding sites during apoptosisin vitro. Blood. 85:1995;532-540.
35. Cook S. J., McCormick F. Inhibition by cAMP of Ras-dependent activation of Raf. Science. 262:1993;1069-1072.
36. ras. J. Biol. Chem. 269:1994;3534-3538.
37. Wu J., Dent P., Jelinek T., Wolfman A., Weber M. I., Sturgill T. W. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science. 262:1993;1065-1068.
38. Graves L. M., Bornfeldt K. E., Raines E. W., Potts B. C., Macdonald S. G., Ross R., Krebs E. G. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc. Natl. Acad. Sci. USA. 90:1993;10300-10304.
39. Mastronicola M. R., Piccoli R., D'Alessio G. Key extracellular and intracellular steps in the antitumor action of seminal ribonuclease. Eur. J. Biochem. 230:1995;242-249.
40. Nitta K., Ozaki K., Ishikawa M., Furusawa S., Hosono M., Kawauchi H., Sassaki K., Takayanage Y., Tsuiki S., Hakomori S. Inhibition of cell proliferation byRana catesbeianaRana japonica. Cancer Res. 54:1994;920-927.
41. Ravi R. K., Weber E., McMahon M., Williams J. R., Baylin S., Mal A., Harter M. L., Dillehay L. E., Claudio P. P., Giordano A., Nelkin B. D., Mabry M. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J. Clin. Invest. 101:1998;153-159.
42. Blackburn P., Moore S. Pancreatic ribonuclease. Enzymes. 15:1982;317-433.
43. Bond M. D., Strydom D. J., Vallee B. L. Characterization and sequencing of rabbit, pig and mouse angiogenins: Discernment of functionally important residues and regions. Biochem. Biophys. Acta. 1162:1993;177-186.